Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22609314 | 0.84 | TAS2R14 (0.42) | LMNAALDH1A1NPSR1TAS2R14HPGD | |
| SCHEMBL23453736 | 0.82 | POLB (0.44) | LMNAALDH1A1NPSR1MAPT | |
| SCHEMBL22609348 | 0.74 | PRKAG1 (0.45) | MAPT | |
| SCHEMBL8061283 | 0.70 | ESR1 (0.54) | LMNAALDH1A1TAS2R14HPGDTSHR | |
| SCHEMBL15491999 | 0.69 | ESR2 (0.76) | LMNAALDH1A1NPSR1TAS2R14 | |
| SCHEMBL23486293 | 0.67 | HAO2 (0.44) | — | |
| SCHEMBL7474018 | 0.66 | KDM4E (0.60) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL23012223 | 0.66 | TAS2R14 (0.55) | TAS2R14 | |
| SCHEMBL23453728 | 0.66 | MEN1 (0.57) | LMNA | |
| SCHEMBL6320202 | 0.64 | OPRM1 (0.62) | LMNAALDH1A1NPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | PNPO, XDH, GLS | LMNA 3881/4885ALDH1A1 149/4885NPSR1 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.